UK’s healthcare AI firm Huma secures €73.3M from AstraZeneca, Hitachi Ventures, others

London-based Huma, a global healthcare AI company, announced on Tuesday that it has secured $80M (approximately €73.3M) in a Series D funding round.

New and existing strategic and financial investors, including AstraZeneca, Hat Technology Fund 4 by HAT SGR, HV Fund by Hitachi Ventures, and Leaps by Bayer, participated in Series D.

With this round, the company has now raised over $300M.

Dan Vahdat, Founder and CEO of Huma, says, “We are here to accelerate the adoption of digital and AI across care and research, and we do that by making the building of digital health solutions for care and research easy. We like to think of Huma Cloud Platform as much like Shopify but for digital health instead of e-commerce. We believe when digital and AI are scaled, they become affordable for both the poor and the rich. They remain consistent and will help us transition medicine from being reactive to proactive.”

Launches Huma Cloud

Alongside its Series D, the UK company also announced the launch of its Huma Cloud Platform.

The platform is a technology ecosystem meant to support the company’s digital health initiatives and enable others to launch and scale their projects efficiently.

With this cloud platform and its regulatory foundation, the company aims to reduce the time it takes to develop and launch digital health projects at scale from years to just a few days.

The Huma Cloud Platform is built to serve the company’s existing regulated products.

In 2023, the London-based company achieved the milestone of becoming the first and only configurable, disease-agnostic FDA Class II, EuMDR Class IIb, and Saudi FDA Class C platform.

This reduces the cost, time, and risks associated with bringing digital health projects to life through the Huma Cloud Platform.

The company is now making this platform available to customers which comes with a Software Development Kit (SDK) to enable the accelerated development of similar applications or to embed functionalities into their existing solutions.

Huma has teamed up with Google and other partners to develop advanced AI models, such as “10x Nurse,” which reduces administrative tasks and automates patient review processes with human oversight.

This allows for more efficient management of chronic diseases and real-time monitoring while also supporting small startups and enterprises.

This shift in focus allows for greater attention on project or venture success rather than being preoccupied with scaling technology or managing regulatory burdens.

Huma: Accelerate the adoption of digital solution

Founded by Dan Vahdat, Huma is a global healthcare AI company on a mission to accelerate the adoption of digital solutions in care and research.

Currently, the company’s modular platforms are used by more than 3,000 hospitals and clinics, with over 35M screened users and 4M registered users in healthcare. They have powered over 800 studies, supporting about 1 million participants across research.

The company is renowned for its role in major national healthcare projects worldwide, from the US and the UK to Germany, Greece, and Saudi Arabia, and for collaborating with most large pharmaceutical companies.

The company’s U.S. business has grown significantly since its launch with new reimbursement codes, claims the company.

The RPM product, built on top of the Huma Cloud Platform for respiratory use cases, now covers 140,000 contracted lives.

As a result of all these successes, the company has doubled its revenue year-on-year and is targeting to become profitable this year.

Dr Juergen Eckhardt, EVP, Head of Leaps by Bayer and Pharmaceuticals Business, Development & Licensing, says, “We have known Huma for several years, and we’ve been impressed by their remarkable progress. We have seen this first-hand. They have demonstrated strong growth and excellent metrics. With their next-generation AI capabilities and Huma Cloud platform, Huma can partner with pharma companies to deliver efficient digital health solutions to patients focused on predictive and proactive care.”